Back to top

Analyst Blog

Mylan, Inc.’s (MYL - Analyst Report) impending acquisition of Agila Specialties  – the injectable drugs division of India’s Strides Arcolab  – for $1.6 billion in cash moved a step towards closure with clearances from the India's Foreign Investment Promotion Board and the Cabinet Committee on Economic Affairs. Mylan intends to fund the deal through a $1 billion senior unsecured bridge term loan in addition to its available cash balance and existing lines of credit.

Through this deal, announced in Feb 2013, Mylan intends to strengthen its presence in the high potential generic injectables market. The deal is expected to close by year-end. At the time of announcing the deal, Mylan had stated that the deal should boost its 2013 adjusted earnings per share immediately after closure.

The global generic injectables market is highly lucrative and is expected to grow at a compound annual growth rate of 13% from 2011-2017 with many drugs losing patent protection. The addition of Agila should boost Mylan’s injectable generic portfolio significantly. The merged entity is expected to account for 70% of the market demand for injectables.

Mylan, one of the largest players in the global generics market, has a presence in more than 140 countries. As of Aug 22, 2013, the company had 179 Abbreviated New Drug Application (ANDAs) pending approval by the U.S. Food and Drug Administration, representing $84 billion in annual sales. These include 42 first-to-file opportunities, representing $23.8 billion in annual sales.

The data released by IMS Health is for the twelve-month period ending Dec. 31, 2012. The successful completion of the deal with Agila will boost these numbers significantly.

Mylan’s generic unit has seen quite a few launches over the past few months. One of the important recent launches includes the company's generic version of Pfizer Inc.’s (PFE - Analyst Report) erectile dysfunction drug Viagra.  

Mylan carries a Zacks Rank #3 (Hold). Actavis, Inc. (ACT - Analyst Report) and Akorn, Inc. (AKRX - Snapshot Report) appear to be well placed in the generic space with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%